A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an AMI
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Ramipril; Valsartan
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms PARADISE-MI
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Oct 2017 This trial has been suspended in Portugal.
- 06 Jan 2017 Status changed from not yet recruiting to recruiting.
- 08 Oct 2016 New trial record